VEGFA and hypertensive disorder: Certain anti-VEGF drugs, such as bevacizumab, sorafenib and sunitinib, currently employed in cancer therapies, have been shown to increase patients’ risk of suffering hypertension, as a consequence of their VEGF inhibiting effect [14,15,43,44].